The conversation discusses the possibility and safety of adding minoxidil sulfate to mesotherapy with dutasteride. Users are inquiring if anyone has tried this combination.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
The conversation is about experimenting with topical Viagra or Cialis for hair loss, including methods for dissolving the tablets. The user is also using herbal oil massages and considering using Ethanol/Propylene Glycol for better dissolution.
The conversation is about finding a reliable source for topical dutasteride, with mentions of MinoxidilMax and Minoxidil Express as previous and potential suppliers. Suggestions include using telehealth services or local compounding pharmacies for a consistent supply.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
The conversation is about finding a legitimate and affordable Chinese source for RU58841 powder for hair loss treatment. It suggests choosing a vendor with good reviews and testing the product for authenticity.
PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.
The conversation discusses sourcing Topilutamide (fluridil) as a treatment for hair loss, with users comparing it to RU58841 and finasteride. Users share their experiences with various treatments, including testosterone, DHT gel, and Proviron, while expressing difficulty in finding Topilutamide.
Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.
The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.
Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.
A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.
The conversation discusses the effectiveness of commercial Low-Level Laser Therapy (LLLT) devices for hair growth, suggesting they are underpowered compared to the ideal energy output shown in medical research. A user plans to build a custom helmet that meets the required specifications for effective treatment.
Topical spironolactone is discussed for hair loss treatment, with mentions of DIY solutions and dermatologist compounding. Users inquire about regrowth and sourcing the treatment.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
Finasteride and dutasteride are essential for stopping hair loss, while natural remedies are ineffective. Minoxidil can be added if needed, but blocking DHT is crucial.
An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.
The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
Finasteride and Dutasteride are under review in the EU due to concerns about side effects like depression, but they are unlikely to be banned. Access to these medications varies, with easier availability in the UK compared to some EU countries.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.